Pharmacological and behavioral effects of MCAM: a long-acting, μ opioid receptor antagonist for treatment of opioid overdose and opioid abuse disorder

MCAM 的药理和行为影响:一种长效、μ阿片受体拮抗剂,用于治疗阿片类药物过量和阿片类药物滥用障碍

基本信息

项目摘要

Methocinnamox (MCAM) is a long-acting µ-opioid receptor antagonist that may have distinct advantages in the treatment of both opioid overdose and opioid abuse disorder. We propose to evaluate MCAM using in vitro and in vivo measures, comparing the actions of MCAM with those of the opioid antagonists naltrexone and naloxone, that are currently used to treat abuse and overdose, respectively. We hypothesize that differences in pharmacological properties, including binding kinetics and non-surmountablility by opioids of abuse, will distinguish MCAM from those of the other opioid receptor antagonists. In vitro, we will compare MCAM to naloxone for kinetics of association/dissociation, surmountability by opioid agonists (fentanyl, morphine), the duration of antagonism (is MCAM irreversible?), and determine the pharmacological characteristics of MCAM at multiple cellular signaling pathways. In vivo measures will be taken in rats to ascertain the duration of action and insurmountability of MCAM in several relevant preparations. Reversal of μ opioid receptor agonist- (morphine and fentanyl) induced respiratory depression will be evaluated using whole body plethysmography. The relative duration of overdose protection afforded by MCAM versus naloxone will be measured in this preparation as well. Models of protection against opioid abuse will utilize measures of the reinforcing effects of the μ opioid receptor agonist remifentanil. The relative insurmountability and duration of action of MCAM versus naltrexone (currently used to treat abuse) in blocking the reinforcing effects of remifentanil will be established in this preparation. The smallest dose of MCAM that is effective when given daily in preventing the reinforcing effects of remifentanil will provide information on the rate of delivery that would be appropriate in a sustained-release formulation of MCAM. Comparisons will also be made of the relative ability of MCAM versus naloxone to elicit withdrawal in opioid- dependent rats. Lastly, because current µ opioid analgesic drugs will not be effective if a long-acting antagonist (e.g., MCAM) is used to treat abuse and/or overdose, we will assess the feasibility of peripherally-restricted administration of kappa opioid receptor agonists for use as analgesic agents in the presence of MCAM. Activation of peripheral kappa opioid receptors that are expressed on peripheral pain-sensing neurons can produce a level of analgesia equivalent to that produced by a local anesthetic and therefore may be a good approach for the treatment of pain in individuals with long-term blockade of µ opioid receptor function. Together, this work will provide needed information about whether MCAM offers substantial advantage over naloxone and naltrexone in blocking or preventing the actions of opioid drugs of abuse.
美罗华(MCAM)是一种长效的阿片受体拮抗剂,在 阿片类药物过量和阿片滥用障碍的治疗。我们建议使用体外和体外方法评估MCAM 体内测量,比较MCAM与阿片类拮抗剂纳曲酮和纳洛酮的作用, 目前分别用于治疗滥用和过量用药。我们假设, 药理学特性,包括结合动力学和阿片类药物滥用无法克服的,将 将MCAM与其他阿片受体拮抗剂区分开来。在体外,我们将MCAM与 纳洛酮的结合/解离动力学,阿片类激动剂(芬太尼,吗啡)的可控性, 拮抗持续时间(MCAM不可逆?),并测定MCAM的药理特性 多条细胞信号通路。将在大鼠身上采取活体措施,以确定作用持续时间和 MCAM在几种相关准备中的不可逾越。μ阿片受体激动剂吗啡的逆转作用 和芬太尼)引起的呼吸抑制将使用全身体积描记进行评估。相对的 在该制剂中也将测量MCAM与纳洛酮提供的过量保护的持续时间。 预防阿片滥用的模型将利用μ阿片受体增强效应的措施 激动剂瑞芬太尼。MCAM与纳曲酮的相对不可克服性和作用持续时间(目前 用于治疗滥用)在阻断瑞芬太尼的强化作用中将在该制剂中确立。这个 每日有效的最小剂量的MCAM预防瑞芬太尼的强化作用 提供在MCAM缓释制剂中适用的递送速率的信息。 还将比较MCAM和纳洛酮诱导阿片类药物戒断的相对能力。 依赖的老鼠。最后,因为目前的阿片类止痛药如果是长效拮抗剂就不会有效 (例如,MCAM)用于治疗滥用和/或过量用药,我们将评估外周限制的可行性 Kappa阿片受体激动剂在MCAM存在时用作止痛剂。激活 在外周痛觉神经元上表达的外周kappa阿片受体可以产生水平的 止痛效果相当于局部麻醉剂,因此可能是一种很好的治疗方法 长期阻断阿片受体功能的个体疼痛的治疗。共同努力,这项工作将 提供有关MCAM是否比纳洛酮和纳曲酮具有实质性优势的所需信息 阻止或防止阿片类药物滥用的行为。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM P CLARKE其他文献

WILLIAM P CLARKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM P CLARKE', 18)}}的其他基金

Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia
DOR-KOR 异聚体介导的外周镇痛变构分子的鉴定
  • 批准号:
    10608439
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
Development of a phenotypic screening assay for novel compounds that inhibit peripheral pain-sensing neurons
开发抑制外周痛觉神经元的新型化合物的表型筛选试验
  • 批准号:
    10650640
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
Pharmacological and behavioral effects of MCAM: a long-acting, μ opioid receptor antagonist for treatment of opioid overdose and opioid abuse disorder
MCAM 的药理和行为影响:一种长效、μ阿片受体拮抗剂,用于治疗阿片类药物过量和阿片类药物滥用障碍
  • 批准号:
    10091419
  • 财政年份:
    2019
  • 资助金额:
    $ 46.18万
  • 项目类别:
Aging, peripheral pain and analgesia
衰老、末梢疼痛和镇痛
  • 批准号:
    8824054
  • 财政年份:
    2015
  • 资助金额:
    $ 46.18万
  • 项目类别:
KOR agonist functional selectivity in peripheral sensory neurons
KOR 激动剂在外周感觉神经元中的功能选择性
  • 批准号:
    9301785
  • 财政年份:
    2015
  • 资助金额:
    $ 46.18万
  • 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
  • 批准号:
    8972021
  • 财政年份:
    2014
  • 资助金额:
    $ 46.18万
  • 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
  • 批准号:
    8794814
  • 财政年份:
    2014
  • 资助金额:
    $ 46.18万
  • 项目类别:
Regulation of Kappa opioid receptor-mediated signaling and peripheral analgesia
Kappa 阿片受体介导的信号传导和外周镇痛的调节
  • 批准号:
    8632174
  • 财政年份:
    2014
  • 资助金额:
    $ 46.18万
  • 项目类别:
Regulation of DOR-KOR heteromer formation in pain-sensing neurons
痛觉神经元中 DOR-KOR 异聚体形成的调节
  • 批准号:
    8824055
  • 财政年份:
    2014
  • 资助金额:
    $ 46.18万
  • 项目类别:
Regulation of opioid receptor function in trigeminal ganglion
三叉神经节阿片受体功能的调节
  • 批准号:
    8094524
  • 财政年份:
    2009
  • 资助金额:
    $ 46.18万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 46.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 46.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 46.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了